{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_notes_note in Note (approximate match)
Status:
Investigational
Source:
NCT03700294: Phase 1 Interventional Terminated Advanced Solid Tumors
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:riletamotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:tapderimotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:alrefimotide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:retatrutide [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00099580: Phase 2 Interventional Completed Congestive Heart Failure
(2005)
Source URL:
Class:
PROTEIN
AC-2592 (glucagon-like peptide 1, or GLP-1) was being in development by Amylin Pharmaceuticals for the treatment of severe congestive heart failure. AC-2592 is a glucagon like peptide 1 receptor agonist.
Status:
Investigational
Source:
NCT04123613: Phase 2 Interventional Completed Kidney Diseases
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01227564: Phase 2 Interventional Completed Alzheimer's Disease
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03578029: Phase 2 Interventional Terminated Junctional Epidermolysis Bullosa
(2019)
Source URL:
Class:
PROTEIN
